Clinical trial
Rosiglitazone for Clozapine Induced Glucose Metabolism Impairment
NCT00337350 · Massachusetts General Hospital, Other · Completed
Key facts
| NCT number | NCT00337350 |
|---|---|
| Title | Rosiglitazone for Clozapine Induced Glucose Metabolism Impairment |
| Official title | A Double-Blind, Placebo-Controlled Trial of Rosiglitazone for Clozapine Induced Glucose Metabolism Impairment: Bergman's Minimal Model Analysis |
| Lead sponsor | Massachusetts General Hospital, Other |
| Collaborators | National Alliance for Research on Schizophrenia and Depression Stanley Medical Research Institute |
| Status | Completed |
| Phase | Phase 4 |
| Study type | Interventional |
| Conditions | Schizophrenia |
| Intervention type | Drug |
| Interventions | rosiglitazone, placebo |
| Enrollment | 20 |
| Start date | Sep 1, 2003 |
| Primary completion | Jan 1, 2011 |
| Completion | Jan 1, 2011 |
| First posted | Jun 15, 2006 |
| Last update posted | May 8, 2015 |
| Countries | United States |
At a glance
- 1–9 Study sites
- Yes Results posted
- None Linked FDA submissions
Counts are shown as ranges. Exact figures, trends and every underlying record are available in Orca1.
About ClinicalTrials.gov studies
ClinicalTrials.gov is the U.S. National Library of Medicine's registry of clinical studies conducted around the world. Contact and investigator details are not shown here.
Source: U.S. National Library of Medicine (NLM), ClinicalTrials.gov · Source date: